The Swedish-British company AstraZeneca will continue testing its coronavirus vaccine. Researchers have developed
They suspended vaccine trials on September 6 -researchers found transverse myelitis in one of the volunteers. This is an inflammation of the spinal cord that affects part of the width of the spinal cord. It is characterized by weakness and numbness of the extremities, deficits in sensitivity and motor skills. Scientists did not rule out that the cause of the disease was the AstraZeneca vaccine.
The coronavirus vaccine from AstraZeneca isone of several in the world that reached the third stage of testing. Others include vaccines from Moderna, Pfizer / BioNTech and companies from China, as well as Russia's Sputnik V.
New world anti-record: 96.5 thousand cases in India per day
AZD1222 is developed by Oxford University andby Vaccitech. It uses a chimpanzee viral vector based on an attenuated version of the common common cold virus that causes infections in chimpanzees and contains SARS-CoV-2 genetic material. After vaccination, a surface spike protein is produced, which prepares the immune system to attack the SARS-CoV-2 virus.
Results, published in The Lancet,confirmed that administration of AZD1222 resulted in a fourfold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants one month after vaccination. All participants showed an activation of the T-cell immune response, which peaked by day 14 and persisted for 2 months after injection.
See also:
- The Russian vaccine against COVID-19 entered civilian circulation, but there are many claims to it
- On day 3 of illness, most patients with COVID-19 lose their sense of smell and often suffer from a runny nose
- Scientists have found out why children are the most dangerous carriers of COVID-19